Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells

Occurrence of Secondary Acute Myeloid Leukemia in a Patient with Breast Cancer after Chemotherapy

GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy

Drug resistance constitutes one of the main obstacles for clinical recovery of acute myeloid leukemia (AML) patients. Therefore, the treatment of AML requires new strategies, such as adding a third drug. To address whether GATA2 could act as a regulator of chemotherapy resistance in human leukemia cells, we observed KG1a cells and clinical patients' AML cells with a classic drug (Cerubidine) an...

Correction: GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy

[This corrects the article DOI: 10.1371/journal.pone.0170630.].

acute myeloid leukemia (aml): the role of intensive induction chemotherapy

intensive induction therapy-in acute myeloid leukemia (aml), as in some other systemic malignancies- is a strategy fundamentally different from post-remission strategies. approaches like consolidation treatment, prolonged mainte nance, and autologous or allogeneic transplantation in the first remission are directed against minimal residual disease with a malignant cell population having survive...

Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.

The role of Survivin in the pathogenesis of leukemia was explored in order to discover the effective avenues for gene therapy. Most primary leukemia cells isolated from patients as well as three leukemia cell lines (HL-60, K562, and U937) all expressed Survivin gene. To investigate the relationship between Survivin and chemotherapeutic resistance, HL-60 cells were treated with daunorubicin (DNR...